AI for Bio · Model

JAM / JAM-2

Closed de novo antibody and VHH design models aimed at hard multi-pass membrane targets such as GPCRs

AntibodiesAI-native biotechUnited StatesActive中文

Overview

NameJAM / JAM-2 · aliases: JAM, JAM-2
Full nameThe technical report gives no expanded form
Ambiguous names (not auto-linked)JAM
FamilyPart of the JAM family
OrganizationNabla Bio
Organization typeAI-native biotech
CountryUnited States
Model classDesign (antibody / VHH)
DomainAntibodies (also: Proteins)
First release† partly verified · product update
Basis: No later than that month: the technical report was covered by a third party; the primary page carries no date
Note: The previous generation's preprint is from 2025-05; the company page's entry date format is ambiguous and is not used source
Other milestones
  • First public evidence: † · Third-party coverage of the technical report source
  • Preprint v1: † · Preprint of the previous generation source
Latest update† unverified · product update
Basis: Follow-on report on T-cell-engaging multispecific antibodies against peptide-MHC class I targets
The follow-on report extends to peptide-MHC class I targets and includes a dual-variant antibody, with cryo-EM confirmation by an imaging service provider; the report itself carries no version date and the month comes from a third-party post, so it is treated as unverified source
The most recent sourced event, not a claim that nothing changed since.
StatusActive · A follow-on report within 12 months, dated only to the month and unverified
OpennessCode: Closed
Weights: Closed
No public weights or code; the material is a company-hosted technical report, not peer reviewed
Benchmarks reported0 counted · none of the 44
Wet-lab validation4 recorded campaigns
Unverified fields† first_release, latest_update, training_data.a_public, wetlab_validation[3]
As of2026-11-16

What it does

Designs antibodies and VHHs de novo for multi-pass membrane targets such as GPCRs, ion channels and transporters; the newer generation extends output to drug-like VHH-Fc and full-length mAb formats, supports user-specified epitopes and steers at inference time from validated molecules. It sits with closed antibody design efforts such as Chai-2 and Latent-X/X2, opposite the academic open route of Germinal.

Benchmarks reported

None of the 44 benchmarks. This model is on the zero-pairing list.

How it evaluates itself: Target Set 1: 16 unseen targets; Head-to-head vs Chai-2 numbers; Epitope-directed set; GPCR native-cell binding; Experiment-guided steering

Other evaluations (outside the 44)

  • Comparison with another closed model's published numbers (Comparison against baselines only) Self-reported: Compares published binding outcomes on overlapping targets rather than re-running the other model
  • Own wet-lab evaluation on hard targets (Wet-lab validation) Self-reported: The target-set, epitope-directed and native-cell experiments are all developer-defined and map to no benchmark on this site

Developers report: Developers report fully computational design of drug-like VHH-Fc and full-length mAbs with binders on all 16 unseen targets, epitope-level control and activity against GPCRs in native cells.

Independent evidence: No independent evidence found. The material is a company-hosted technical report, not peer reviewed, and no third-party re-test was found

Training data

Group in Figure 7: Public data + wet lab for validation only.

ClassValueDetail
a. Public databasesNot disclosedThe technical report does not state training data sources source
b. Private or licensed dataNot disclosed source
c. Own wet-lab data used for trainingNot disclosedPretraining is undisclosed; inference-time steering prompted by validated molecules is not training source
d. Wet lab used only for validationYesAll reported results come from newly run wet-lab screens source

Wet-lab validation

Every rate carries its numerator and denominator. Claims that could not be verified are shown as unverified, without numbers; different paper versions are separate entries.

Target set 1 (16 unseen targets) (technical report)
Targets 16 · Designs tested — · Hits 16 · Success 16/16 targets · Best affinity —

Denominator basis: 16 targets, 45 designs per modality per target, a binary binding readout; hits counted per target
Mean per-target success is 39% and 18% for the two modalities; of the 16 targets, 2 reached picomolar and 7 single-digit nanomolar
Executor: Run by the developer; the report contains no independent experimental arm

Self-reported · † · verified · source
Epitope-directed set (10 further targets) (technical report)
Targets 10 · Designs tested — · Hits — · Success — · Best affinity —

Denominator basis: 20 user-specified epitopes per target and about 600 designs per epitope; the report gives no per-epitope denominator
The report states that on half the targets 30-70% of epitopes yielded binders; a range without per-target denominators
Executor: Run by the developer

Self-reported · † · verified · source
GPCR binding in native cells (technical report)
Targets 2 · Designs tested — · Hits — · Success 11.7% and 3.8% (per-target rates, denominators not given) · Best affinity —

Denominator basis: Two chemokine receptors tested in cells; the report gives no design-count denominator
The report also claims that test-time compute scaling raises success substantially; self-reported
Executor: Run by the developer

Self-reported · † · verified · source
Experiment-guided steering (agonist antibodies) (secondary coverage)
Targets — · Designs tested — · Hits — · Success — · Best affinity —

Denominator basis: Second-hand source only, no denominator
Generating like molecules prompted by one validated molecule is a case study, not a measured evaluation
Executor: Executor undisclosed

Self-reported · † · †unverified · source

Background

  • Organization: The developer is headquartered in Massachusetts as an AI-native antibody design company spun out of a university lab; headcount of about twenty-odd comes from public data aggregators.
  • Funding: An $11M seed in 2021-12 led by two venture firms and a $26M Series A in 2024-05 led by one firm. A 2026 Series B listed by a data aggregator has no company announcement or second source and is not used.
  • Products and partnerships: It collaborates with three large pharmaceutical companies; in 2025-10 it signed a second multi-year deal with one of them with potential value above a billion dollars including milestones, upfront undisclosed. Competitors include the developers of Chai-2 and Latent-X/X2.
  • Related models: Chai-2, Latent-X / Latent-X2, Germinal

Reading notes

  1. All results are self-reported, not peer reviewed, and there is no independent experimental arm.
  2. "Binders on all 16 targets" is a per-target statement; per-design hit rates are much lower and the two must not be swapped.
  3. The target set overlaps another closed model's study to enable comparison, and the comparison is between published results.
  4. Pretraining data is entirely undisclosed, so it cannot be filed as public-data-only.

Caveats

  1. Neither the first nor the follow-on report has a primary-page date, so dates are month-level only.
  2. The agonist count is second-hand and that figure is no longer given on the site.
  3. A second-hand claim that the previous generation got one hit in twenty thousand designs could not be found in the report.
  4. It reports no benchmark on this site, so comparison with other models is only indirect, through each party's own wet-lab protocol.

Sources

  1. Technical report PDF (technical report)
  2. Third-party coverage (2025-11-20) (news) · 2025-11-20
  3. Imaging provider blog (relating to the follow-on report) (blog)
  4. Seed round coverage (news)

Corrections

2 corrections
FieldWasNowBasisFound
wetlab_validationCited the number of agonist antibodies (300+)The number is second-hand and unverified; removedsource2026-11-16
latest_updateRecorded only up to the technical reportAdded the 2026-06 follow-up report on peptide-MHC class I, marked unverified (month-level)source2026-11-16

Part of the AI for Bio benchmarks survey · all 112 models · open in the explorer. Record as of 2026-11-16.